Proscia, Inc.

Proscia, Inc. is an enterprise digital pathology and AI software platform company serving diagnostic laboratories, academic medical centers, health systems, pharmaceutical companies, contract research organizations (CROs), and biotech firms. The company develops and markets Concentriq, a purpose-built digital pathology platform offered in three modules: Concentriq LS for life sciences R&D and biomarker discovery; Concentriq AP for clinical laboratory digitization and workflow management; and Concentriq AP-Dx, which is FDA-cleared for primary diagnosis and supports both late-stage clinical trials and routine diagnostic operations. Proscia Aperture is a precision medicine analytics solution that converts pathology data into real-time, point-of-diagnosis patient insights for drug development and real-world evidence generation. The platform integrates AI analysis tools for pathologists and scientists, enabling automated image analysis, data harmonization across siloed sources, and collaborative research workflows. The company serves over 12,000 daily users across major diagnostic reference labs, 16 of the top 20 pharmaceutical companies, and leading academic institutions including Cleveland Clinic and PathGroup. Proscia holds FDA clearance for diagnostic applications and is recognized by KLAS as a leader in digital pathology. The company has raised significant capital to advance AI-driven pathology solutions and has been acknowledged by Fast Company and Fierce Biotech for innovation in AI and digital health.